PMV Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 73.32 million compared to USD 57.85 million a year ago. Basic loss per share from continuing operations was USD 1.61 compared to USD 1.28 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.155 USD | +0.70% | -0.46% | -30.65% |
09/05 | PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
12/04 | Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.81% | 110M | |
+26.65% | 49.18B | |
+0.44% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+12.47% | 26.09B | |
-21.91% | 18.71B | |
+8.41% | 13.26B | |
+31.14% | 12.32B | |
-0.36% | 11.99B |
- Stock Market
- Equities
- PMVP Stock
- News PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022